Heart Failure and Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Heart Failure and Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
J Heart Lung Transplant. 2016 Nov;35(11):1337-1347. doi: 10.1016/j.healun.2016.06.003. Epub 2016 Jun 7.
Studies assessing mortality and morbidity in adult transplant recipients with congenital heart disease (CHD) are limited. We conducted a systematic review and meta-analysis comparing post-transplant outcomes in these 2 populations.
After conducting an electronic database search, we selected studies evaluating mortality, cause-specific mortality, and risk of reoperation and dialysis in adult CHD vs non-CHD patients. We used random-effects models for the meta-analysis.
Thirty-day mortality was significantly higher in CHD vs non-CHD patients (risk ratio [RR], 2.18; 95% confidence interval [CI], 1.62-2.93; I = 41%). This was influenced by increased mortality in Fontan/Glenn patients compared with non-CHD patients (RR, 3.3; 95% CI, 1.89-5.77; I = 0%). Mortality at 1 and 5 years was higher in the CHD population, although neither achieved statistical significance. Ten-year mortality was significantly lower in CHD patients (RR, 0.75; 95% CI, 0.60-0.95, I = 42%). Deaths caused by malignancy, infection, rejection, and cardiac allograft vasculopathy were decreased in CHD patients, although only death from malignancy achieved significance. Death secondary to primary graft failure, stroke, and hemorrhage was significantly higher in CHD patients. Risk of reoperation and dialysis were not statistically different between the 2 groups.
Although adult CHD patients have higher early mortality, post-transplantation long-term survival is superior to non-CHD recipients. The challenge is to identify the CHD patients who will benefit from transplantation vs those who are higher risk.
评估患有先天性心脏病(CHD)的成年移植受者的死亡率和发病率的研究有限。我们进行了一项系统评价和荟萃分析,比较了这两种人群的移植后结局。
在进行电子数据库搜索后,我们选择了评估死亡率、特定原因死亡率以及成年 CHD 与非 CHD 患者再手术和透析风险的研究。我们使用随机效应模型进行荟萃分析。
30 天死亡率在 CHD 与非 CHD 患者中明显更高(风险比 [RR],2.18;95%置信区间 [CI],1.62-2.93;I = 41%)。这是由于与非 CHD 患者相比,Fontan/Glenn 患者的死亡率增加(RR,3.3;95%CI,1.89-5.77;I = 0%)。CHD 人群的 1 年和 5 年死亡率较高,但均未达到统计学意义。10 年死亡率在 CHD 患者中明显较低(RR,0.75;95%CI,0.60-0.95,I = 42%)。CHD 患者的恶性肿瘤、感染、排斥和心脏移植物血管病导致的死亡率降低,但只有恶性肿瘤导致的死亡率具有统计学意义。因原发性移植物衰竭、中风和出血导致的死亡在 CHD 患者中明显更高。再手术和透析的风险在两组之间无统计学差异。
尽管成年 CHD 患者的早期死亡率较高,但移植后的长期生存率优于非 CHD 受者。挑战在于确定哪些 CHD 患者将从移植中受益,哪些患者风险更高。